Videos

The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo provided commentary on the significant findings from the EMBOLISE trial presented at the 2024 International Stroke Conference. [WATCH TIME: 4 minutes]

Ahead of the 2024 MDA Conference, the medical advisor and care center director at Muscular Dystrophy Association talked about the track sessions he will be cochairing at the meeting. [WATCH TIME: 5 minutes]

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital shared thoughts on the promising advancements in the multiple sclerosis field for 2024. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending February 10, 2024. [WATCH TIME: 3 minutes]

The research scientist at Kessler Foundation discussed a recently funded study focused on improving memory and learning deficits in patients with multiple sclerosis by combining a cognitive rehabilitation program with a cycling initiative enriched with virtual reality elements. [WATCH TIME: 7 minutes]

The professor of neurology at the Zucker School of Medicine at Hofstra-Northwell talked about recently updated epilepsy care guidelines that shift the focus to outpatient care, incorporating broader aspects like care coordination, medication access, and patient-identified needs. [WATCH TIME: 5 minutes]

The associate professor of neurology at Weill Cornell Medicine talked about a recent study that revealed that minimally invasive surgery significantly reduced the risk of mortality in patients with nontraumatic intracerebral hemorrhage. [WATCH TIME: 4 minutes]

The chief of the division of stroke and hospital neurology at Weill Cornell Medicine shared some of his thoughts on the promising clinical trials being presented at the 2024 International Stroke Conference. [WATCH TIME: 3 minutes]

The postdoctoral research fellow at Brigham and Women’s Hospital and Harvard Medical School provided answers to a recently published study highlighting the burden of care and infrequent use of novel exon-skipping drugs for Duchenne in clinical settings. [WATCH TIME: 3 minutes]

The associate professor of neurology at NYU Grossman School of Medicine talked about the need for increased awareness in the medical community to address the underutilization of surgical interventions for refractory focal epilepsy. [WATCH TIME: 4 minutes]

The staff neurologist at Cleveland Clinic’s Mellen Center for MS detailed some of the negative impacts issues with access to neurologists and MS care centers can have on patient diagnosis and longterm prognosis. [WATCH TIME: 4 minutes]

Tanuja Chitnis, MD, shares possible course of action if NFL levels begin to rise during treatment.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, raise important questions about the extent to which biomarkers can aid in patient care as well as their limitations.

The professor of neurology at Stony Brook University Medical Center discussed the significance of shared decision making in multiple sclerosis care and promising developments in treatment strategies. [WATCH TIME: 3 minutes]

The head of the division of movement disorder at the Northwestern University Feinberg School of Medicine provided perspective on the impact of a newly published staging system that defines Parkinson disease by biologic features, not symptoms. [WATCH TIME: 4 minutes]

The professor of neurology at NYU Grossman School of Medicine talked about the importance of aligning leadership roles with personal passions for women in the field of neurology pursuing their careers in medicine. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending February 3, 2024. [WATCH TIME: 3 minutes]

The associate professor of neurology at Vanderbilt University Medical Center discussed exploring promising opportunities in other phases outside of the acute phase of ischemic stroke. [WATCH TIME: 3 minutes]

The adjunct professor of human genetics at Emory University School of Medicine discussed previous research on Rett syndrome that initially provided crucial insight on the neuromuscular condition in adult populations. [WATCH TIME: 2 minutes]

The founder and executive director of the Sumaira Foundation shared her patient journey living with NMOSD and the progress that has been made in the field over the past decade. [WATCH TIME: 4 minutes]

The chief executive officer of Aruna Bio discussed the reasons for the failure of neuroprotective agents in ischemic stroke trials and why AB126 has potential to restore neurodegeneration in such affected patients. [WATCH TIME: 3 minutes]

The chair of Allegheny Health Network’s department of neurology provided insight on his clinical experiences with migraine medicine and how the field needs to adapt to the ongoing changes to treatment options. [WATCH TIME: 4 minutes]

The director of NYU Langone’s Comprehensive Epilepsy Center discussed the infrequent prevalence of febrile seizures in toddlers prior to sudden death and the difficulty with toeing the line on being overly cautious and reasonable. [WATCH TIME: 4 minutes]

The associate professor of neurology at the Cleveland Clinic Lerner Institute provided insight on a recently published meta-analysis identifying independent genome-wide significant loci whose expression is associated with Parkinson disease risk. [WATCH TIME: 5 minutes]

The founder and executive director of the Sumaira Foundation discussed the increasing amount of misdiagnosis in rare diseases such as NMOSD and how it impacts these patients in terms of care and support. [WATCH TIME: 2 minutes]

The senior vice president of research at Gain Therapeutics talked about preclinical findings from a study assessing GT-02287, an agent in development for the treatment of GBA1 Parkinson disease, and future plans for clinical trials. [WATCH TIME: 7 minutes]

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, talk about the practical use of biomarkers in treatment decision making.

Tanuja Chitnis, MD, explains how higher neurofilament light chain levels can signal disease activity in MS.

The founder and executive director of the Sumaira Foundation shared her patient perspective of Health Canada’s approval of inebilizumab in terms of its implications for patients and how it paves the way for future treatments in NMOSD. [WATCH TIME: 3 minutes]

The chief executive officer of ClearPoint Neuro discussed how the company’s SmartFrame OR Stereotactic System can facilitate neurosurgery and the next steps in integrating it into clinical settings. [WATCH TIME: 4 minutes]